Dare Bioscience Files Routine 8-K on Jan 26, 2024
Ticker: DARE · Form: 8-K · Filed: Jan 26, 2024 · CIK: 1401914
Complexity: simple
Sentiment: neutral
Topics: routine-filing, corporate-governance
TL;DR
**Dare Bioscience filed a routine 8-K, no major news.**
AI Summary
Dare Bioscience, Inc. filed an 8-K on January 26, 2024, reporting an event that occurred on January 23, 2024. This filing is a standard current report, indicating no major new developments like acquisitions or significant executive changes, but rather a routine disclosure. For investors, this means there's no immediate news from this specific filing that would drastically alter the company's valuation or strategic direction, suggesting a period of operational normalcy.
Why It Matters
This filing is a standard disclosure, indicating no immediate material changes in the company's operations or leadership that would impact its stock price.
Risk Assessment
Risk Level: low — The filing is a standard current report with no specific events detailed that would introduce new risks or significant changes.
Analyst Insight
Given this is a routine filing with no new material information, a smart investor would maintain their current position or continue with their existing research without immediate action based solely on this 8-K.
Key Numbers
- 001-36395 — Commission File Number (identifies the company's registration with the SEC)
- 20240123 — Conformed Period of Report (the date of the earliest event reported in the filing)
- 20240126 — Filed As Of Date (the date the filing was submitted to the SEC)
Key Players & Entities
- Dare Bioscience, Inc. (company) — the registrant filing the 8-K
- January 23, 2024 (date) — date of earliest event reported
- January 26, 2024 (date) — date the 8-K was filed
- 001-36395 (other) — Commission File Number
- 3655 Nobel Drive, Suite 260, San Diego, CA 92122 (other) — principal executive offices address
Forward-Looking Statements
- Dare Bioscience, Inc. will continue to file routine disclosures without significant material events in the near term. (Dare Bioscience, Inc.) — medium confidence, target: 2024-04-30
FAQ
What is the purpose of this 8-K filing by Dare Bioscience, Inc.?
This 8-K filing is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934,' indicating it's a routine disclosure of an event that occurred on January 23, 2024, as per the 'Date of Report (Date of earliest event reported)'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 23, 2024, as stated under 'Date of Report (Date of earliest event reported): January 23, 2024'.
What is the full business address of Dare Bioscience, Inc. as listed in the filing?
The full business address of Dare Bioscience, Inc. is '3655 Nobel Drive, Suite 260, San Diego, CA 92122', as specified in the 'BUSINESS ADDRESS' section of the filing.
What is the Commission File Number for Dare Bioscience, Inc.?
The Commission File Number for Dare Bioscience, Inc. is '001-36395', as listed in the filing under 'Commission File Number'.
Does this 8-K filing indicate any simultaneous satisfaction of other filing obligations?
No, the filing explicitly states 'Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):' and all checkboxes for Rule 425, Rule 14a-12, Rule 14d-2(b), and Rule 13e-4(c) are unchecked (indicated by '☐').
Filing Stats: 1,592 words · 6 min read · ~5 pages · Grade level 10.9 · Accepted 2024-01-26 17:15:12
Key Financial Figures
- $31,667 — the Consulting Period, we will pay her $31,667 per month and will reimburse her the am
- $295,000 — -Layton's current annual base salary is $295,000, which is the same amount it was during
- $386,000 — ch is currently an annualized amount of $386,000, will be reduced by 25%. Following his
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex99-1.htm (EX-99.1) — 23KB
- 0001493152-24-003984.txt ( ) — 252KB
- dare-20240123.xsd (EX-101.SCH) — 3KB
- dare-20240123_lab.xml (EX-101.LAB) — 33KB
- dare-20240123_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 of this report and Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section
Item 7.01 of this report and Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing. Item 9.01 Financial (d) Exhibits 99.1 Press release issued January 26, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. -3-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: January 26, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -4-